Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Payables (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Payables for 7 consecutive years, with $10.2 million as the latest value for Q4 2025.

  • Quarterly Payables rose 164.3% to $10.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.2 million through Dec 2025, up 164.3% year-over-year, with the annual reading at $10.2 million for FY2025, 164.3% up from the prior year.
  • Payables for Q4 2025 was $10.2 million at Beam Therapeutics, up from $9.5 million in the prior quarter.
  • The five-year high for Payables was $14.1 million in Q1 2023, with the low at $1.6 million in Q4 2023.
  • Average Payables over 5 years is $6.9 million, with a median of $7.2 million recorded in 2021.
  • The sharpest move saw Payables tumbled 82.09% in 2023, then surged 175.95% in 2025.
  • Over 5 years, Payables stood at $7.5 million in 2021, then rose by 20.81% to $9.0 million in 2022, then crashed by 82.09% to $1.6 million in 2023, then skyrocketed by 139.39% to $3.9 million in 2024, then surged by 164.3% to $10.2 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $10.2 million, $9.5 million, and $10.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.